Vincerx Pharma, Inc. Common Stock
VINC
VINC was delisted on the 22nd of April, 2025.
35 hedge funds and large institutions have $15.7M invested in Vincerx Pharma, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 12 reducing their positions, and 3 closing their positions.
18% more capital invested
Capital invested by funds: $13.3M → $15.7M (+$2.36M)
3% less funds holding
Funds holding: 36 → 35 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
67% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
+$193K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$52.4K |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$49.7K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.75K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
-$452K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$358K |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$106K |
| 4 |
TC
Tejara Capital
London,
United Kingdom
|
-$82.3K |
| 5 |
BlackRock
New York
|
-$70K |
VINC Hedge Fund Activity: Q2 2023 in Review
35 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q2 2023, worth a combined $15.7M — up 18% from $13.3M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of VINC and 2 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 4 added.
The largest buyer was Walleye Capital, opening a new position worth an estimated $193K. The largest seller was Long Focus Capital Management, cutting an estimated $452K.
- 35 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q2 2023, down from 36 in Q1 2023.
- Funds reported $15.7M of Vincerx Pharma, Inc. Common Stock stock for Q2 2023, up 18% quarter-over-quarter.
- 2 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q2 2023 and 3 closed out, a net change of -1 holder.
- The largest Vincerx Pharma, Inc. Common Stock buyer in Q2 2023 was Walleye Capital, an estimated $193K added.
- The largest Vincerx Pharma, Inc. Common Stock seller in Q2 2023 was Long Focus Capital Management, an estimated $452K sold.
Based on aggregated 13F filings for Q2 2023.